Leállítva3. fázis
Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)
A legfontosabb adatok
- Ki végzi
- Pulmocide Ltd
- Hol
- Ann Arbor, Baltimore, Houston, Jacksonville, La Jolla, Los Angeles, Madison, Minneapolis, Philadelphia, Pittsburgh, Sacramento, St Louis és The Bronx (Egyesült Államok)Mind a 15 helyszín megnézéseMég 19 másik országban, 56 helyszínen
- Azonosító
- Állapot
- Leállítva
- Fázis
- 3. fázis
- Résztvevők
- 85 fő vett részt
- Kezdés
- 2022. jún. 14.
- Befejezés
- 2025. dec. 29.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- PC945
- Placebo
- A regiszteradat frissítve
- 2026. április 30.
- Miért állt le
- The study was terminated by the Sponsor based on a sample size recalculation interim analysis which showed a numerically lower favorable response rate and a numerically higher mortality rate in the opelconazole arm compared to the control arm.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 6 feltétel megnézéseKevesebb
Ki vehet részt
- Participant has proven or probable IPA according to the modified 2019 European Organization for Research and Treatment of Cancer/ Mycoses Study Group Education and Research Consortium (EORTC/MSGERC) consensus definitions or according to the 2010 International Society for Heart and Lung Transplantation (ISHLT) consensus statements for the definitions of infections in cardiothoracic transplant recipients
- Participant's IPA has failed to respond to adequate antifungal therapy
Ki nem vehet részt
- Participant with a known or suspected concomitant medical condition or post-surgery complication that, in the opinion of the Investigator, may jeopardize adherence to the protocol requirements or impede the accurate measurement of efficacy or may be an unacceptable additional risk to the Participant should he/she participate in the study
- Participant who has previously received PC945
- Participant with a known history of allergy, hypersensitivity, or any previous serious reaction to any component of the PC945 or placebo formulations
- Participant who has recently received, is receiving or due to receive at any time during the study, an investigational medicinal agent that does not have any regulatory approved indications. Subjects who are participating in any other trials e.g., Observational, diagnostic or using medications with an approved indication may be allowed to participate after consultation with the sponsor on an individual basis
Helyszínek itt: Egyesült Államok
Még 19 másik országban, 56 helyszínen
- Ann Arbor, MichiganHospital not named in the registry
- Baltimore, MarylandHospital not named in the registry
- Houston, TexasHospital not named in the registry
- Houston, TexasHospital not named in the registry
- Jacksonville, FloridaHospital not named in the registry
- La Jolla, CaliforniaHospital not named in the registry
- Los Angeles, CaliforniaHospital not named in the registry
- Clinical R SiteLos Angeles, Egyesült Államok
- Madison, WisconsinHospital not named in the registry
- Minneapolis, MinnesotaHospital not named in the registry
- Philadelphia, PennsylvaniaHospital not named in the registry
- Pittsburgh, PennsylvaniaHospital not named in the registry
- Sacramento, CaliforniaHospital not named in the registry
- St Louis, MissouriHospital not named in the registry
- The Bronx, New YorkHospital not named in the registry
A vizsgálatról
Mit akar kideríteni a vizsgálat
To assess the safety and efficacy of nebulized PC945 in combination with systemic antifungal therapy for the treatment of refractory IPA
A vizsgálat 2 csoportja
- PC945A vizsgált kezelés
PC945 dose, administered via nebulizer, twice daily
- PlaceboPlacebo, összehasonlításként
PC945-placebo administered via nebulizer, twice daily
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Double-blind, Randomized, Placebo-controlled Study to Assess the Safety and Efficacy of Nebulized PC945 When Added to Systemic Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)
- A regiszteradat frissítve
- 2026. április 30.